US EditionPromising vaccine may prevent certain cancers from returning
The ELI-002 2P vaccine induced strong immune responses in 21 of 25 patients, correlating with delayed cancer recurrence and longer survival in high-risk KRAS-mutated cases.
- Researchers at UCLA Health recently announced phase 1 results from the AMPLIFY-201 phase 1 trial testing the ELI-002 2P vaccine on 25 patients.
- Because colorectal and pancreatic cancers often recur, patients with minimal residual disease face high relapse risk, motivating development of a KRAS mutations-targeted vaccine platform.
- Laboratory results revealed 21 patients generated KRAS-specific T cells, showing vaccine-induced immune activation recently.
- Among patients with strong responses, 17 patients showed much lower recurrence or death risk versus historical controls, and investigators said randomized phase 2 results would be highly meaningful.
- Researchers said the vaccine offers a promising approach to generate durable immune responses against KRAS-driven cancers, notably pancreatic cancer, without the complexity of personalized vaccines.
22 Articles
22 Articles
‘Extremely Promising’: New Vaccine Could Prevent Recurrence Of Deadly Colon, Pancreatic Cancer
A new experimental vaccine has been developed that appears to be successful in preventing recurrences of the deadly colorectal and pancreatic cancers. A study led by the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, tested the ELI-002 2P vaccine on 25 patients previously treated for pancreatic and colorectal cancers. The vaccine could “help prevent or delay cancer recurrence in high-risk patients whose tumors …
A team of scientists from several American universities and research institutions has developed a new experimental vaccine, ELI-002 2P, aimed at specific mutations in cancer cells. The vaccine primarily targets pancreatic and colon cancer, which are among the most dangerous oncological diseases. The vaccine has so far passed the first phase of clinical trials, according to the results, it could significantly extend the lives of patients and redu…
Promising vaccine may prevent certain cancers from returning
(NewsNation) — An experimental cancer vaccine has shown promising results in keeping pancreatic and colorectal cancers from coming back. In a clinical trial led by the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, researchers tested the vaccine on 25 patients who had previously been treated for pancreatic and colorectal cancers. Colorectal cancer is the third most common cancer diagnosed in both men and women …
‘Extremely Promising’: New Vaccine Could Prevent Recurrence Of Deadly Colon, Pancreatic Cancer - Conservative Angle
A new experimental vaccine has been developed that appears to be successful in preventing recurrences of the deadly colorectal and pancreatic cancers. A study led by the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, tested the ELI-002 2P vaccine on 25 patients previously treated for pancreatic and colorectal cancers. The vaccine could “help prevent or delay cancer recurrence in high-risk patients whose tumors …
Coverage Details
Bias Distribution
- 79% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
